Bevacizumab with or without Radiation Therapy in Treating Patients with Recurrent Glioblastoma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeAgeTrial IDs
Phase IITreatment18 and overRTOG 1205
NCI-2012-01732, NCT01730950

Trial Description

Summary

TRIAL STATUS: Active

This randomized phase II trial studies how well bevacizumab with or without radiation therapy works in treating patients with glioblastoma that has returned after a period of improvement. Monoclonal antibodies, such as bevacizumab, may block tumor growth by targeting certain cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. It is not yet known whether bevacizumab is more effective with or without radiation therapy in treating patients with recurrent glioblastoma.

Further Study Information

PRIMARY OBJECTIVES:

I. To establish an improvement in overall survival in recurrent glioblastoma multiforme (GBM) patients receiving bevacizumab and re-irradiation compared with patients receiving bevacizumab alone.

SECONDARY OBJECTIVES:

I. To estimate and compare the rate of objective response in patients with measurable disease.

II. To estimate and compare the 6-month progression-free survival rate.

III. To estimate and compare progression-free survival.

IV. To estimate and compare the rate of treatment adverse events.

V. To estimate and compare the rate of >= grade 3 acute or delayed central nervous system (CNS) toxicity.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive bevacizumab intravenously (IV) over 30-90 minutes every 2 weeks.

ARM II: Patients receive bevacizumab as in Arm I and undergo radiation therapy using intensity-modulated radiation therapy (IMRT), 3-dimensional conformal radiation therapy (3D-CRT), or proton beam radiation therapy (RT) 5 days a week for 2 weeks.

In both arms, courses with bevacizumab repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 2 months for 1 year, every 6 months for 1 year and then annually thereafter.

Eligibility Criteria

Inclusion Criteria:

Histopathologically proven diagnosis of glioblastoma or variants (gliosarcoma, giant cell glioblastoma etc); patients will be eligible if the original histology was lower-grade glioma and a subsequent diagnosis of glioblastoma or gliosarcoma is made

Patients who did not have recent surgery for their glioblastoma must have shown unequivocal radiographic evidence for tumor progression by contrast-enhanced MRI scan (or CT scan for patients with non-compatible devices) within 21 days prior to registration; Note: patients who did have surgery with a post-operative contrast-enhanced scan falling outside the 5-week window prior to registration, per definition of recent surgery, must have a repeat magnetic resonance imaging (MRI) scan (or computed tomography [CT] scan for patients with non-compatible devices) within 21 days prior to registration

Patients must have passed an interval of 6 months or greater between completion of prior radiotherapy and registration; if patients have not passed an interval of at least 6 months, they may still be eligible if they meet one or more of the following criteria:

  • New areas of tumor outside the original radiotherapy fields as determined by the investigator, or
  • Histologic confirmation of tumor through biopsy or resection, or
  • Nuclear medicine imaging, magnetic resonance (MR) spectroscopy, or MR perfusion imaging consistent with true progressive disease, rather than radiation necrosis obtained within 28 days of registration AND an interval of at least 90 days between completion of radiotherapy and registration

Patients unable to undergo MR imaging because of non-compatible devices can be enrolled provided CT scans are obtained and are of sufficient quality; patients without non-compatible devices may not use CT scans performed to meet this requirement

Prior history of standard dose CNS radiation of 60 Gy in 30 fractions or 59.4 Gy in 1.8 Gy fractions, or equivalent or lower doses

Patients who have received prior treatment with non-standard radiation therapy (RT) dose and fractionation, interstitial brachytherapy, stereotactic radiosurgery, etc. are eligible as long as the criterion is met or approved by a principal investigator

Patients must have recovered from the toxic effects of prior therapy, and there must be a minimum time of 28 days prior to registration from the administration of any investigational agent or prior cytotoxic therapy with the following exceptions:

14 days from administration of vincristine

42 days from administration of nitrosoureas

21 days from administration of procarbazine

Patients having undergone recent resection of their glioblastoma (within 5 weeks prior to registration) must have recovered from the effects of surgery; for CNS related core or needle biopsies, a minimum of 7 days must have elapsed prior to registration

Residual disease following resection of recurrent glioblastoma is not mandated for eligibility into the study; to best assess the extent of residual disease post-operatively, a post-operative or intra-operative MRI scan (or CT scan for patients with non-compatible devices) must be performed prior to registration and should be within 96 hours post surgery (although 24 hours would be optimum)

History/physical examination, including neurologic examination, within 14 days prior to registration

Karnofsky performance status >= 60 within 14 days prior to registration

Complete blood count (CBC)/differential obtained within 14 days prior to registration, with adequate bone marrow function

Absolute neutrophil count (ANC) >= 1,500 cells/mm^3

Platelets >= 75,000 cells/mm^3

Hemoglobin >= 9.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 9.0 g/dl is acceptable)

Total bilirubin =< 2.0 mg/dL

Serum glutamic oxaloacetic transaminase (SGOT) or aspartate aminotransferase (AST) =< 2.5 times the upper limit of normal

Serum creatinine =< 1.8 mg/dL

Urine protein: creatinine (UPC) ratio < 1.0 within 14 days prior to registration OR urine dipstick for proteinuria =< 2 positive (+) (patients discovered to have > 2+ proteinuria on dipstick urinalysis at baseline must have a UPC ratio done that is < 1.0 to be eligible; if the UPC ratio is >= 1.0 then the patients should undergo a 24-hour urine collection and must demonstrate =< 1g of protein in 24 hours to be eligible)

Note: UPC ratio of spot urine is an estimation of the 24-hour urine protein excretion; a UPC ratio of 1 is roughly equivalent to a 24-hour urine protein of 1 gm

Patients must not be pregnant (positive pregnancy test) or breast feeding; pregnancy test must be done within 7 days prior to registration; effective contraception (men and women) must be used in patients of child-bearing potential while on study treatment and for 6 months after

Patients on full-dose anticoagulants (e.g., warfarin or low molecular weight [LMW] heparin) must meet both of the following criteria:

No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)

In-range international normalized ratio (INR) (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin, within 14 days prior to registration

Patient must be able to provide study-specific informed consent prior to study entry

Exclusion Criteria:

More than three relapses

Infratentorial, or leptomeningeal evidence of recurrent disease

Recurrent or persistent tumor greater than 6 cm in maximum diameter

Prior therapy with an inhibitor of vascular endothelial growth factor (VEGF) or VEGF receptor (VEGFR) (including bevacizumab)

Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1 year (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)

Severe, active co-morbidity, defined as follows:

Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration

Transmural myocardial infarction within the last 6 months prior to registration

History of stroke or transient ischemic attack within 6 months prior to registration

Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection) or clinically significant peripheral vascular disease

Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration

Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration

Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function other than screening panel and coagulation parameters are not required for entry into this protocol

Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive; protocol specific requirements may also exclude immuno-compromised patients

Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception

Prior allergic reaction to the study drug (bevacizumab)

Prior history of hypertensive crisis or hypertensive encephalopathy

History of a non-healing wound, ulcer, or bone fracture within 90 days (3 months) prior to registration

Gastrointestinal bleeding or any other hemorrhage/bleeding event Common Terminology Criteria for adverse Events (CTCAE), v. 4 grade 3 or greater within 30 days prior to registration

Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration (with the exception of craniotomy)

Trial Contact Information

Trial Lead Organizations / Sponsors / Collaborators

NRG Oncology

  • National Cancer Institute
Christina I. Tsien, Principal Investigator

Trial Sites

U.S.A.

Alabama
Birmingham

University of Alabama at Birmingham Cancer Center

John B. Fiveash
Ph: 205-934-0309

John B. Fiveash
Principal Investigator

Mobile

University of South Alabama Mitchell Cancer Institute

John R. Russell
Ph: 877-904-4367
Email: pfrancisco@usouthal.edu

John R. Russell
Principal Investigator

Arizona
Phoenix

Saint Joseph's Hospital and Medical Center

David G. Brachman
Ph: 877-602-4111

David G. Brachman
Principal Investigator

Scottsdale

Arizona Oncology Services Foundation

David G. Brachman
Ph: 877-602-4111

David G. Brachman
Principal Investigator

Tucson

The University of Arizona Medical Center-University Campus

Baldassarre (Dino) Stea
Ph: 520-626-9008

Baldassarre (Dino) Stea
Principal Investigator

California
Auburn

Sutter Cancer Centers Radiation Oncology Services-Auburn

Christopher Uwe Jones
Ph: 916-454-6618
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Burbank

Providence Saint Joseph Medical Center/Disney Family Cancer Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Burlingame

Mills - Peninsula Hospitals

Christopher Uwe Jones
Ph: 916-454-6618
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Cameron Park

Sutter Cancer Centers Radiation Oncology Services-Cameron Park

Christopher Uwe Jones
Ph: 916-454-6618
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Castro Valley

Eden Hospital Medical Center

Christopher Uwe Jones
Ph: 916-454-6618
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Fresno

Fresno Cancer Center

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Modesto

Memorial Medical Center

Christopher Uwe Jones
Ph: 916-454-6618
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Oakland

Kaiser Permanente Oakland-Broadway

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Palo Alto

Palo Alto Medical Foundation Health Care

Christopher Uwe Jones
Ph: 916-454-6618
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Rancho Cordova

Kaiser Permanente-Rancho Cordova Cancer Center

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Rohnert Park

Rohnert Park Cancer Center

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Roseville

Sutter Cancer Centers Radiation Oncology Services-Roseville

Christopher Uwe Jones
Ph: 916-454-6618
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

The Permanente Medical Group-Roseville Radiation Oncology

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Sacramento

South Sacramento Cancer Center

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Sutter General Hospital

Christopher Uwe Jones
Ph: 916-454-6618
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Santa Clara

Kaiser Permanente Medical Center - Santa Clara

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

South San Francisco

Kaiser Permanente Cancer Treatment Center

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Sunnyvale

Palo Atlo Medical Foundation-Sunnyvale

Christopher Uwe Jones
Ph: 916-454-6618
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Vacaville

Sutter Cancer Centers Radiation Oncology Services-Vacaville

Christopher Uwe Jones
Ph: 916-454-6618
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Colorado
Aurora

University of Colorado Cancer Center - Anschutz Cancer Pavilion

Brian Dennis Kavanagh
Ph: 720-848-0238
Email: brian.kavanagh@ucdenver.edu

Brian Dennis Kavanagh
Principal Investigator

Boulder

Rocky Mountain Cancer Centers-Boulder

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Colorado Springs

Memorial Hospital Colorado Springs

Brian Dennis Kavanagh
Ph: 720-848-0238
Email: brian.kavanagh@ucdenver.edu

Brian Dennis Kavanagh
Principal Investigator

Penrose-Saint Francis Healthcare

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Fort Collins

Poudre Valley Hospital

Brian Dennis Kavanagh
Ph: 720-848-0238
Email: brian.kavanagh@ucdenver.edu

Brian Dennis Kavanagh
Principal Investigator

Greeley

North Colorado Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Longmont

Longmont United Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Parker

Parker Adventist Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Wheat Ridge

SCL Health Lutheran Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Connecticut
Bridgeport

Saint Vincent's Medical Center

Nicholas A. Blondin
Ph: 203-581-6587
Email: twhite@stvincents.org

Nicholas A. Blondin
Principal Investigator

New Britain

The Hospital of Central Connecticut

Neal B. Goldberg
Ph: 860-224-5986
Email: neal.goldberg@hhchealth.org

Neal B. Goldberg
Principal Investigator

Delaware
Newark

Christiana Care Health System-Christiana Hospital

Adam Raben
Ph: 302-733-6227

Adam Raben
Principal Investigator

Florida
Deerfield Beach

University of Miami Sylvester Comprehensive Cancer Center at Deerfield Beach

Fazilat Ishkanian
Ph: 305-243-4363
Email: Sylvester@emergingmed.com

Fazilat Ishkanian
Principal Investigator

Jacksonville

Baptist Cancer Institute

Mark Emerson Augspurger
Ph: 904-202-7051

Mark Emerson Augspurger
Principal Investigator

Miami

University of Miami Miller School of Medicine-Sylvester Cancer Center

Fazilat Ishkanian
Ph: 305-243-4363
Email: Sylvester@emergingmed.com

Fazilat Ishkanian
Principal Investigator

Georgia
Atlanta

Emory University Hospital Midtown

Ian Richard Crocker
Ph: 404-778-1868

Ian Richard Crocker
Principal Investigator

Emory University/Winship Cancer Institute

Ian Richard Crocker
Ph: 404-778-1868

Ian Richard Crocker
Principal Investigator

Northside Hospital

Sahar Esther Rosenbaum
Ph: 404-303-3355

Sahar Esther Rosenbaum
Principal Investigator

Piedmont Hospital

Adam Wayne Nowlan
Ph: 404-425-7943
Email: ORS@piedmont.org

Adam Wayne Nowlan
Principal Investigator

Savannah

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

Joshua Terry Mckenzie
Ph: 800-622-6877

Joshua Terry Mckenzie
Principal Investigator

Idaho
Boise

Saint Alphonsus Cancer Care Center-Boise

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Illinois
Chicago

John H Stroger Jr Hospital of Cook County

Thomas E. Lad
Ph: 312-864-9002
Email: tlad@cookcountyhhs.org

Thomas E. Lad
Principal Investigator

Northwestern University

Priya Uday Kumthekar
Ph: 312-695-1301
Email: cancer@northwestern.edu

Priya Uday Kumthekar
Principal Investigator

University of Chicago Comprehensive Cancer Center

Steven J. Chmura
Ph: 773-834-7424

Steven J. Chmura
Principal Investigator

University of Illinois

Matthew Koshy
Ph: 312-355-3046

Matthew Koshy
Principal Investigator

Joliet

Joliet Oncology-Hematology Associates Limited

Kulumani M. Sivarajan
Ph: 815-730-3098
Email: maureenc@jolietoncology.com

Kulumani M. Sivarajan
Principal Investigator

Naperville

Edward Hospital/Cancer Center

Oh-Hoon Kwon
Ph: 630-646-6075

Oh-Hoon Kwon
Principal Investigator

New Lenox

UC Comprehensive Cancer Center at Silver Cross

Steven J. Chmura
Ph: 773-834-7424

Steven J. Chmura
Principal Investigator

Plainfield

Edward Hospital/Cancer Center?Plainfield

Oh-Hoon Kwon
Ph: 630-646-6075

Oh-Hoon Kwon
Principal Investigator

Warrenville

Northwestern Medicine Cancer Center Warrenville

Vinai Gondi
Ph: 630-352-5489
Email: Claudine.Gamster@CadenceHealth.org

Vinai Gondi
Principal Investigator

Indiana
Fort Wayne

Parkview Hospital Randallia

Brian K. Chang
Ph: 260-373-8888
Email: parkviewresearch@parkview.com

Brian K. Chang
Principal Investigator

Radiation Oncology Associates PC

Brian K. Chang
Ph: 260-373-8888
Email: parkviewresearch@parkview.com

Brian K. Chang
Principal Investigator

Kentucky
Lexington

Baptist Health Lexington

Marta S. Hayne
Ph: 859-260-6425

Marta S. Hayne
Principal Investigator

University of Kentucky/Markey Cancer Center

John Lee Villano
Ph: 859-257-3379

John Lee Villano
Principal Investigator

Maine
Scarborough

Maine Medical Center- Scarborough Campus

Ian Jared Bristol
Ph: 207-396-8090
Email: wrighd@mmc.org

Ian Jared Bristol
Principal Investigator

Maryland
Baltimore

University of Maryland/Greenebaum Cancer Center

Young Kwok
Ph: 800-888-8823

Young Kwok
Principal Investigator

Bel Air

Upper Chesapeake Medical Center

Young Kwok
Ph: 800-888-8823

Young Kwok
Principal Investigator

Massachusetts
Boston

Massachusetts General Hospital Cancer Center

Kevin Shawn Oh
Ph: 617-726-3603
Email: koh2@partners.org

Kevin Shawn Oh
Principal Investigator

Burlington

Lahey Hospital and Medical Center

Brian J. Scott
Ph: 781-744-8027

Brian J. Scott
Principal Investigator

Michigan
Ann Arbor

Saint Joseph Mercy Hospital

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Detroit

Saint John Hospital and Medical Center

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Kalamazoo

West Michigan Cancer Center

Sunil Nagpal
Ph: 269-373-7458

Sunil Nagpal
Principal Investigator

Livonia

Saint Mary Mercy Hospital

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Pontiac

Saint Joseph Mercy Oakland

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Royal Oak

William Beaumont Hospital-Royal Oak

Inga Siiner Grills
Ph: 248-551-7695

Inga Siiner Grills
Principal Investigator

Troy

William Beaumont Hospital - Troy

Inga Siiner Grills
Ph: 248-551-7695

Inga Siiner Grills
Principal Investigator

Warren

Saint John Macomb-Oakland Hospital

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Minnesota
Bemidji

Sanford Clinic North-Bemidgi

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Missouri
Kansas City

Research Medical Center

Rakesh Gaur
Ph: 816-932-2677
Email: SLCIResearch1@saint-lukes.org

Rakesh Gaur
Principal Investigator

Saint Luke's Hospital of Kansas City

Rakesh Gaur
Ph: 816-932-2677
Email: SLCIResearch1@saint-lukes.org

Rakesh Gaur
Principal Investigator

Rolla

Phelps County Regional Medical Center

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Saint Louis

Barnes-Jewish West County Hospital

Jiayi Huang
Ph: 800-600-3606
Email: info@siteman.wustl.edu

Jiayi Huang
Principal Investigator

Washington University School of Medicine

Jiayi Huang
Ph: 800-600-3606
Email: info@siteman.wustl.edu

Jiayi Huang
Principal Investigator

Springfield

Mercy Hospital Springfield

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Montana
Billings

Billings Clinic Cancer Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Nebraska
Omaha

Nebraska Methodist Hospital

Tien-Shew William Huang
Ph: 402-354-5144

Tien-Shew William Huang
Principal Investigator

Nevada
Henderson

Comprehensive Cancer Centers of Nevada - Henderson

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Las Vegas

Comprehensive Cancer Centers of Nevada

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Comprehensive Cancer Centers of Nevada - Central Valley

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Comprehensive Cancer Centers of Nevada - Northwest

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Comprehensive Cancer Centers of Nevada-Summerlin

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Reno

Saint Mary's Regional Medical Center

Jonathan S. Tay
Ph: 775-770-7414

Jonathan S. Tay
Principal Investigator

New Jersey
Mount Holly

Virtua Memorial

Lemuel S. Ariaratnam
Ph: 609-914-6762

Lemuel S. Ariaratnam
Principal Investigator

New Brunswick

Rutgers Cancer Institute of New Jersey

Sharad Goyal
Ph: 732-235-8675

Sharad Goyal
Principal Investigator

Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital

Sharad Goyal
Ph: 732-235-8675

Sharad Goyal
Principal Investigator

Voorhees

Virtua Voorhees

Lemuel S. Ariaratnam
Ph: 609-914-6762

Lemuel S. Ariaratnam
Principal Investigator

New York
Bay Shore

Southside Hospital

Jonathan Petrus Sandberg Knisely
Ph: 516-562-3467

Jonathan Petrus Sandberg Knisely
Principal Investigator

New Hyde Park

North Shore-LIJ Health System/Center for Advanced Medicine

Jonathan Petrus Sandberg Knisely
Ph: 516-562-3467

Jonathan Petrus Sandberg Knisely
Principal Investigator

North Carolina
Charlotte

Carolinas Medical Center/Levine Cancer Institute

Ashley Love Sumrall
Ph: 980-442-5261
Email: ashley.sumrall@carolinas.org

Ashley Love Sumrall
Principal Investigator

Greensboro

Cone Health Cancer Center

Matthew Alexander Manning
Ph: 336-832-0821

Matthew Alexander Manning
Principal Investigator

North Dakota
Bismarck

Sanford Bismarck Medical Center

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Fargo

Roger Maris Cancer Center

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Ohio
Akron

Akron General Medical Center

Mitchel L. Fromm
Ph: 330-344-6348

Mitchel L. Fromm
Principal Investigator

Summa Akron City Hospital/Cooper Cancer Center

Desiree E. Doncals
Ph: 330-375-6101

Desiree E. Doncals
Principal Investigator

Barberton

Summa Barberton Hospital

Desiree E. Doncals
Ph: 330-375-6101

Desiree E. Doncals
Principal Investigator

Cleveland

Case Western Reserve University

Simon Shek-Man Lo
Ph: 216-844-1038
Email: simon.lo@uhhospitals.org

Simon Shek-Man Lo
Principal Investigator

Columbus

Riverside Methodist Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Kettering

Kettering Medical Center

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Oklahoma
Oklahoma City

University of Oklahoma Health Sciences Center

Terence S. Herman
Ph: 405-271-4272
Email: julie-traylor@ouhsc.edu

Terence S. Herman
Principal Investigator

Oregon
Clackamas

Clackamas Radiation Oncology Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Portland

Legacy Good Samaritan Hospital and Medical Center

Andrew Y. Kee
Ph: 800-220-4937
Email: cancer@lhs.org

Andrew Y. Kee
Principal Investigator

Providence Portland Medical Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Providence Saint Vincent Medical Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Pennsylvania
Abington

Abington Memorial Hospital

Wayne H. Pinover
Ph: 215-481-6741
Email: wpinover@amh.org

Wayne H. Pinover
Principal Investigator

Bethlehem

Saint Luke's University Hospital-Bethlehem Campus

Nimisha Deb
Ph: 484-526-3583
Email: infolink@slhn.org

Nimisha Deb
Principal Investigator

Dunmore

Northeast Radiation Oncology Center

Maria Werner-Wasik
Ph: 215-955-5331
Email: maria.werner-wasik@jefferson.edu

Maria Werner-Wasik
Principal Investigator

Hershey

Penn State Hershey Cancer Institute-Clinical Trials Office

Henry Wagner
Ph: 717-531-3779
Email: CTO@hmc.psu.edu

Henry Wagner
Principal Investigator

Philadelphia

Aria Health-Torresdale Campus

Maria Werner-Wasik
Ph: 215-955-5331
Email: maria.werner-wasik@jefferson.edu

Maria Werner-Wasik
Principal Investigator

Temple University Hospital

Curtis T. Miyamoto
Ph: 215-728-2983

Curtis T. Miyamoto
Principal Investigator

Thomas Jefferson University Hospital

Maria Werner-Wasik
Ph: 215-955-6084
Email: maria.werner-wasik@jefferson.edu

Maria Werner-Wasik
Principal Investigator

Pittsburgh

Allegheny General Hospital

Stephen Michael Karlovits
Ph: 412-359-3981
Email: skarlovi@wpahs.org

Stephen Michael Karlovits
Principal Investigator

West Reading

Reading Hospital

Albert Yuen
Ph: 610-988-9323

Albert Yuen
Principal Investigator

South Carolina
Charleston

Medical University of South Carolina

Scott Michael Lindhorst
Ph: 843-792-9321

Scott Michael Lindhorst
Principal Investigator

Greenville

Greenville Health System Cancer Institute-Eastside

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Greenville Health System Cancer Institute-Faris

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Greer

Gibbs Cancer Center-Pelham

Patricia C. Griffin
Ph: 800-486-5941

Patricia C. Griffin
Principal Investigator

Greenville Health System Cancer Institute-Greer

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Seneca

Greenville Health System Cancer Institute-Seneca

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Spartanburg

Greenville Health System Cancer Institute-Spartanburg

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Spartanburg Medical Center

Patricia C. Griffin
Ph: 800-486-5941

Patricia C. Griffin
Principal Investigator

South Dakota
Rapid City

Rapid City Regional Hospital

Michael J. Swartz
Ph: 605-716-3982
Email: research@rcrh.org

Michael J. Swartz
Principal Investigator

Sioux Falls

Sanford USD Medical Center - Sioux Falls

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Tennessee
Knoxville

Tennessee Cancer Specialists-Dowell Springs

Marcio Augusto Fagundes
Ph: 865-244-3209

Marcio Augusto Fagundes
Principal Investigator

Thompson Cancer Survival Center

Grant Michael Clark
Ph: 865-541-1812

Grant Michael Clark
Principal Investigator

Maryville

Blount Memorial Hospital

Grant Michael Clark
Ph: 865-541-1812

Grant Michael Clark
Principal Investigator

Texas
Austin

Austin Cancer Centers-Central Austin

Mateo Ziu
Ph: 512-324-7991

Mateo Ziu
Principal Investigator

Austin Cancer Centers-North

Mateo Ziu
Ph: 512-324-8301
Email: mziu@seton.org

Mateo Ziu
Principal Investigator

University Medical Center Brackenridge

Mateo Ziu
Ph: 512-324-7991

Mateo Ziu
Principal Investigator

Galveston

University of Texas Medical Branch

Martin Colman
Ph: 409-772-1950
Email: clinical.research@utmb.edu

Martin Colman
Principal Investigator

League City

UTMB Cancer Center at Victory Lakes

Martin Colman
Ph: 409-772-1950
Email: clinical.research@utmb.edu

Martin Colman
Principal Investigator

Lubbock

Covenant Medical Center-Lakeside

Paul J. Anderson
Ph: 806-723-6039
Email: jaccresearch@covhs.org

Paul J. Anderson
Principal Investigator

Washington
Kennewick

Tri-Cities Cancer Center

George E. Laramore
Ph: 206-598-3498
Email: georgel@uw.edu

George E. Laramore
Principal Investigator

Longview

Saint John Medical Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Seattle

ProCure Proton Therapy Center-Seattle

George E. Laramore
Ph: 206-598-3498
Email: georgel@uw.edu

George E. Laramore
Principal Investigator

University of Washington Medical Center

George E. Laramore
Ph: 206-598-3498
Email: georgel@uw.edu

George E. Laramore
Principal Investigator

Vancouver

PeaceHealth Southwest Medical Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Yakima

North Star Lodge Cancer Center at Yakima Valley Memorial Hospital

Cheryl A. Davison
Ph: 509-574-3530
Email: cheryl.davison@yvmh.org

Cheryl A. Davison
Principal Investigator

West Virginia
Wheeling

Wheeling Hospital/Schiffler Cancer Center

Jondavid Pollock
Ph: 304-243-6442

Jondavid Pollock
Principal Investigator

Wisconsin
Green Bay

Saint Mary's Hospital

James L. Leenstra
Ph: 507-645-2655

James L. Leenstra
Principal Investigator

Saint Vincent Hospital

James L. Leenstra
Ph: 507-645-2655

James L. Leenstra
Principal Investigator

Marinette

Bay Area Medical Center

James L. Leenstra
Ph: 507-645-2655

James L. Leenstra
Principal Investigator

Mukwonago

D N Greenwald Center

Wingate F. Clapper
Ph: 262-928-7632
Email: Chanda.miller@phci.org

Wingate F. Clapper
Principal Investigator

Oconomowoc

Oconomowoc Memorial Hospital-ProHealth Care Inc

Wingate F. Clapper
Ph: 262-928-7632
Email: Chanda.miller@phci.org

Wingate F. Clapper
Principal Investigator

Sturgeon Bay

Door County Cancer Center

James L. Leenstra
Ph: 507-645-2655

James L. Leenstra
Principal Investigator

Waukesha

UW Cancer Center at ProHealth Care

Wingate F. Clapper
Ph: 262-928-7537
Email: Chanda.miller@phci.org

Wingate F. Clapper
Principal Investigator

Waukesha Memorial Hospital

Wingate F. Clapper
Ph: 262-928-7632
Email: Chanda.miller@phci.org

Wingate F. Clapper
Principal Investigator

Canada

Saskatchewan
Regina

Allan Blair Cancer Centre

Tak Hing Patricia Tai
Ph: 306-766-2213

Tak Hing Patricia Tai
Principal Investigator

Saskatoon

Saskatoon Cancer Centre

Duc M. Le
Ph: 306-655-2914

Duc M. Le
Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifier NCT01730950

Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.